OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

Appointments and roles

OS Therapies announced the appointments of Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer. The release states Mr. Clem will lead U.S., U.K., and European commercialization strategy and launch planning for Herlystic (OST-HER2; daznelimgene lisbac), including developing the commercial organization and launch infrastructure and preparing for potential U.S. market entry, subject to regulatory approval. The company described Mr. Knuettel's background in executive finance roles, his experience raising capital, and his role in managing finance, accounting operations, and corporate governance as the company transitions toward commercialization. (Inference: These hires position OS Therapies to focus internal resources on launch preparation and financial stewardship ahead of regulatory decisions.)

Sources: S1

Regulatory planning and timelines

OS Therapies described a regulatory sequence that may see the U.K.'s MHRA reach a decision ahead of the U.S. FDA and the EMA. The company said it is pursuing an MHRA Conditional Marketing Authorization Application (CMAA) under Project Orbis via ILAP with a submission targeted for early in fourth quarter of 2026 and is pursuing a U.S. BLA under the Accelerated Approval pathway and a CMAA in Europe in parallel. (Inference: The company is pursuing multiple regulatory pathways and has provided an internal timeline for at least one submission.)

Sources: S1

Reported non-dilutive funding and payables arrangements

The release says the company has implemented a U.K. R&D refundable tax credit strategy and has received over $3 million in non-dilutive capital to date from VAT refunds, with additional VAT refunds pending, and has accrued over $7 million in R&D Tax Credits that will begin to flow back into OSTUK. In parallel, the company disclosed an agreement with its largest vendors delaying the due date of the majority of its outstanding AP until the second quarter of 2027. (Inference: OS Therapies describes both near-term non-dilutive funding and vendor payment deferrals as part of its cash management.)

Sources: S1

Regulatory designations and clinical context

OS Therapies reiterated that OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD), and Rare Pediatric Disease Designation (RPDD) from the FDA and that the company reported positive data in its Phase 2b clinical trial demonstrating clinically significant benefit in the 12-month event free survival (EFS) primary endpoint and the overall survival (OS) secondary endpoint. (Inference: The company highlights regulatory designations and reported Phase 2b results as context for its commercialization planning.)

Sources: S1

What remains uncertain

• All forward-looking statements in the source are company projections and subject to regulatory review, the timing and outcome of which are uncertain; the press release is an issuer communication and the claims regarding future submissions, approvals, cash inflows, and potential Priority Review Voucher proceeds are not independently verified in the source.
• The reported Phase 2b results and other clinical claims are described by the company; the press release does not include independent trial data tables or third-party verification.